Literature DB >> 28176228

Primary uterine diffuse large B-cell lymphoma (DLBCL) in a patient with prolonged insertion of intrauterine device (IUD).

Takuya Shimizu1, Kazuo Hatanaka1, Hitomi Kaneko1, Toshihide Shimada2, Kazunori Imada3.   

Abstract

A 49-year-old female from China was referred to our hospital after endocervical polypectomy. Twenty years before admission, after the birth of her first child, an intrauterine device (IUD) had been inserted due to the one-child policy in China. She had noticed abnormal vaginal bleeding with a foul smell 3 years before admission. Then the IUD was removed and a polyp was found at the IUD contact site. Two months before admission, endocervical polypectomy was performed. Lymphoma was suspected by histological examination and she was referred to our hospital. Further examination confirmed the diagnosis of primary uterine diffuse large B-cell lymphoma (DLBCL). Subsequently, a combination of three cycles of R-CHOP regimen and involved-field radiation therapy was performed, followed by maintenance therapy with five cycles of rituximab. She has remained in complete remission for over 1 year. This case suggests that chronic inflammation induced by prolonged IUD insertion may contribute to the development of primary uterine lymphoma. To the best of our knowledge, this is the first reported case of DLBCL associated with prolonged IUD insertion.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; Intrauterine device; Uterine polyp

Mesh:

Year:  2017        PMID: 28176228     DOI: 10.1007/s12185-017-2191-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  5 in total

1.  T-cell-rich B-cell lymphoma and Epstein-Barr virus infection of the uterus in a postmenopausal patient with an intrauterine contraceptive device in place for over 20 years.

Authors:  P D Gutman; J P Williams; G S Dveksler; K Hoffmeister; J D Cotelingam
Journal:  Gynecol Oncol       Date:  1998-03       Impact factor: 5.482

2.  Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies.

Authors:  Xavier Castellsagué; Mireia Díaz; Salvatore Vaccarella; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Chris J L M Meijer; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2011-09-12       Impact factor: 41.316

3.  Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

Authors:  Roberto N Miranda; Tariq N Aladily; H Miles Prince; Rashmi Kanagal-Shamanna; Daphne de Jong; Luis E Fayad; Mitual B Amin; Nisreen Haideri; Govind Bhagat; Glen S Brooks; David A Shifrin; Dennis P O'Malley; Chan Y Cheah; Carlos E Bacchi; Gabriela Gualco; Shiyong Li; John A Keech; Ephram P Hochberg; Matthew J Carty; Summer E Hanson; Eid Mustafa; Steven Sanchez; John T Manning; Zijun Y Xu-Monette; Alonso R Miranda; Patricia Fox; Roland L Bassett; Jorge J Castillo; Brady E Beltran; Jan Paul de Boer; Zaher Chakhachiro; Dongjiu Ye; Douglas Clark; Ken H Young; L Jeffrey Medeiros
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

4.  Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.

Authors:  Jina Yun; Seok Jin Kim; Jung A Kim; Jee Hyun Kong; Soo Hyeon Lee; Kihyun Kim; Young Hyeh Ko; Won Seog Kim
Journal:  Acta Haematol       Date:  2009-12-02       Impact factor: 2.195

5.  Primary mesenteric follicular lymphoma associated with mesenteric migration of intrauterine device.

Authors:  Xue-Feng Sun; Jun Feng; Wei Liu
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

  5 in total
  1 in total

1.  Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma.

Authors:  Masatoshi Sakurai; Takaaki Toyama; Taku Kikuchi; Jun Kato; Takayuki Shimizu; Yuya Koda; Daiki Karigane; Yusuke Yamane; Ryohei Abe; Rie Yamazaki; Tomonori Nakazato; Tadaki Nakahara; Masahiro Jinzaki; Shinichiro Okamoto; Takehiko Mori
Journal:  Int J Hematol       Date:  2017-10-09       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.